<DOC>
	<DOCNO>NCT00052026</DOCNO>
	<brief_summary>The purpose study determine whether new medicine , call carvedilol , improve symptom heart function child congestive heart failure ( diminish function heart muscle pump blood body ) . To accomplish , give carvedilol patient diminish heart function congestive heart failure see whether symptom heart function well end 8 month period receive carvedilol compare patient receive carvedilol . We test 2 different dos carvedilol compare additional medicine .</brief_summary>
	<brief_title>Safety Efficacy Study Carvedilol Treat Children With Congestive Heart Failure</brief_title>
	<detailed_description>Overactivity sympathetic nervous system think contribute pathophysiology congestive heart failure ( CHF ) . Blockade sympathetic nervous system β-adrenergic inhibitor could expect ameliorate detrimental effect manner analogous effect angiotensin convert enzyme inhibitor overactive renin-angiotensin system . Carvedilol may superior pure beta-blockers treatment CHF mechanism action block β-receptors also α-receptors , would allow vasodilation reduce afterload fail heart . Since beta-blockers may initially produce negative inotropic effect heart , long term treatment need show benefit removal adrenergic stimulation . The investigator monitor safety efficacy carvedilol administration child chronic CHF due systemic ventricular dysfunction .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Adrenergic alpha-Antagonists</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Male female child birth 17 year age chronic symptomatic CHF due systemic ventricular systolic dysfunction receive standard heart failure therapy eligible . Since adolescent leave ventricular dysfunction similar adult disease , study focus recruitment prepubertal age group child , include child birth Tanner Stage 3 . The number adolescent enrol limited approximately 10 % study enrollment . However , teenager single ventricle morphologic right ventricle systemic ventricle represent important population unique pediatric cardiology . The 10 % limitation apply teenager dilate cardiomyopathy since patient may similar young adult dilated cardiomyopathy . Adolescents define Tanner Stage 4 age 17 . 2 . A diagnosis CHF NYHA Class IIIV ( generally , child older 5 year age ) Ross ' classification CHF Class IIIV ( 12 ) ( generally , child le 5 year old ) least 1 month ( least 2 week , neonate ) prior screen . 3 . An estimated ejection fraction le 40 % patient systemic leave ventricular dysfunction qualitative evidence dilate ventricle moderate systemic ventricular systolic dysfunction patient right ventricular single ventricular physiology , document within 4 week randomization . Patients may enrol base criterion determine site . However , echocardiograms review interpreted Data Coordinating Center ( DCC ) University Utah . Upon subsequent review DCC , determine either ejection fraction great equal 40 % ventricular function moderate severely decreased , patient enrol . However , data analysis base upon finding DCC University Utah . 4 . The etiology cardiomyopathy include idiopathic dilate cardiomyopathy , postviral myocarditis cardiomyopathy , anthracyclineinduced cardiomyopathy , ischemic cardiomyopathy ( e.g. , Kawasaki 's disease , repair anomalous leave coronary artery arise pulmonary artery , dTGA s/p arterial switch ) , cardiomyopathy associate single ventricle ventricular systolic dysfunction , correct transposition , etc . Excluded enrollment dilate cardiomyopathy secondary muscular dystrophy , hemoglobinopathy , HIV , carnitine deficiency , systemic ventricular dysfunction due ventricular outflow obstruction . 5 . Patients undergoing treatment CHF standard CHF therapy , diuretic , digoxin ACE inhibitor . All patient receive ACE inhibitor prior enrollment study unless contraindicate intolerant . If intolerance establish , patient must withdraw drug least one month prior randomization . Other medication hydralazine , nitrate amiodarone may also use . Therapy amiodarone start stop within 2 month randomization . 6 . All patient receive diuretic prior enrollment study unless contraindicate intolerant . Patients must optimal fluid status prior enrollment . 7 . Patients must receive stable regimen standard CHF medication period least one month ( 2 week neonates ) time randomization study . EXCLUSION CRITERIA Patients follow exclude study : 1 . NYHA Ross ' CHF Classification Class I ( asymptomatic ) . 2 . Patients actively list transplantation time entry study anticipate undergo heart transplantation corrective heart surgery 8 month follow entry study . However , patient list transplantation anticipate may wait long period time ( great 8 month ) , Status 2 patient , may consider enrollment study . 3 . Sustained symptomatic ventricular dysrhythmias uncontrolled drug therapy use implantable defibrillator , and/or significant cardiac conduction defect , e.g. , 2nd degree 3rd degree AV block , sick sinus syndrome , unless function pacemaker place . 4 . Uncorrected primary obstructive severe regurgitative valvular disease , nondilated ( restrictive ) hypertrophic cardiomyopathy , significant systemic ventricular outflow obstruction . 5 . Dilated cardiomyopathy secondary muscular dystrophy , hemoglobinopathy , HIV , carnitine deficiency , systemic ventricular dysfunction due ventricular outflow obstruction . 6 . Active myocarditis . 7 . Unacceptable blood pressure heart rate . Sitting ( supine infant ) systolic blood pressure must &gt; 85 mm Hg teen , &gt; 75 mm Hg schoolaged child , &gt; 65 mm Hg infant ( 12 ) . Resting heart rate must great 2nd percentile age ( 13 ) . 8 . Renovascular hypertension evidence pulmonary hypertension ( pulmonary vascular resistance index &gt; 6 Wood unitsm2 ) unresponsive vasodilator agent oxygen , nitroprusside , nitric oxide . 9 . History current clinical evidence moderatetosevere obstructive pulmonary disease reactive airway disease ( e.g. , asthma ) require therapy . 10 . Significant renal ( serum creatinine &gt; 2.0 ) , hepatic ( serum AST and/or ALT &gt; 3 time upper limit normal ) , gastrointestinal , biliary disorder could impair absorption , metabolism , excretion orally administer medication . 11 . Concurrent terminal illness severe disease ( e.g. , active neoplasm ) significant laboratory value ( ) , opinion investigator , could preclude participation survival . 12 . Endocrine disorder primary aldosteronism , pheochromocytoma , hyper hypothyroidism , insulindependent diabetes mellitus . 13 . Unwillingness inability cooperate , parent guardian give consent , child give assent , condition sufficient severity impair cooperation study . 14 . Girls child bear potential pregnant , lactating , sexually active take adequate contraceptive precaution ( e.g. , IUD oral contraceptive 3 month prior entry study ) . 15 . Use investigational drug within 30 day randomization , within 5 halflives investigational drug ( long period apply ) ; investigational vaccine biological agent ( e.g. , monoclonal antibody Synagis ) , may grant exception consultation principal investigator GlaxoSmithKline . 16 . History drug sensitivity allergic reaction ablockers ßblockers . 17 . Use following medication within two week randomization : Monoamine oxidase ( MAO ) inhibitor Calcium entry blocker Alpha blocker , labetalol Disopyramide , flecainide , encainide , moricizine , propafenone Intravenous ßadrenergic agonist ( include intravenous inotropes dobutamine ) intravenous vasodilator agent amrinone milrinone Intravenous CHF medication ( e.g. , diuretic , digoxin ) 18 . Treatment badrenergic blocker , include sotalol carvedilol within 2 month randomization .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Adolescent</keyword>
	<keyword>Adrenergic alpha-Antagonists/therapeutic use</keyword>
	<keyword>Adrenergic alpha-Antagonists/pharmacokinetics</keyword>
	<keyword>Adrenergic alpha-Antagonists/administration &amp; dosage</keyword>
	<keyword>Adrenergic beta-Antagonists/therapeutic use</keyword>
	<keyword>Adrenergic beta-Antagonists/pharmacokinetics</keyword>
	<keyword>Adrenergic beta-Antagonists/administration &amp; dosage</keyword>
	<keyword>Age Factors</keyword>
	<keyword>Carbazoles/therapeutic use</keyword>
	<keyword>Carbazoles/administration &amp; dosage</keyword>
	<keyword>Child</keyword>
	<keyword>Child , Preschool</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>Female</keyword>
	<keyword>Heart Failure , Congestive/etiology</keyword>
	<keyword>Heart Failure , Congestive/drug therapy</keyword>
	<keyword>Heart Failure , Congestive/blood</keyword>
	<keyword>Human</keyword>
	<keyword>Infant</keyword>
	<keyword>Infant , Newborn</keyword>
	<keyword>Male</keyword>
	<keyword>Natriuretic Peptide , Brain/blood</keyword>
	<keyword>Placebos</keyword>
	<keyword>Propanolamines/therapeutic use</keyword>
	<keyword>Propanolamines/administration &amp; dosage</keyword>
	<keyword>Prospective Studies</keyword>
	<keyword>Support , Non-U.S. Gov't</keyword>
	<keyword>Treatment Outcome</keyword>
	<keyword>Ventricular Dysfunction/drug therapy</keyword>
	<keyword>Ventricular Dysfunction/complications</keyword>
	<keyword>Ventricular Dysfunction/blood</keyword>
	<keyword>Ventricular Function/drug effect</keyword>
	<keyword>Ventricular Remodeling/drug effect</keyword>
</DOC>